BACKGROUND: Symptom dimensions have not yet been comprehensively tested as predictors of the substantial heterogeneity in outcomes of antidepressant treatment in major depressive disorder. METHOD: We tested nine symptom dimensions derived from a previously published factor analysis of depression rating scales as predictors of outcome in 811 adults with moderate to severe depression treated with flexibly dosed escitalopram or nortriptyline in Genome-based Therapeutic Drugs for Depression (GENDEP). The effects of symptom dimensions were tested in mixed-effect regression models that controlled for overall initial depression severity, age, sex and recruitment centre. Significant results were tested for replicability in 3637 adult out-patients with non-psychotic major depression treated withcitalopram in level I of Sequenced Treatment Alternatives to Relieve Depression (STAR*D). RESULTS: The interest-activity symptom dimension (reflecting low interest, reduced activity, indecisiveness and lack of enjoyment) at baseline strongly predicted poor treatment outcome in GENDEP, irrespective of overall depression severity, antidepressant type and outcome measure used. The prediction of poor treatment outcome by the interest-activity dimension was robustly replicated in STAR*D, independent of a comprehensive list of baseline covariates. CONCLUSIONS: Loss of interest, diminished activity and inability to make decisions predict poor outcome of antidepressant treatment even after adjustment for overall depression severity and other clinical covariates. The prominence of such symptoms may require additional treatment strategies and should be accounted for in future investigations of antidepressant response.
RCT Entities:
BACKGROUND: Symptom dimensions have not yet been comprehensively tested as predictors of the substantial heterogeneity in outcomes of antidepressant treatment in major depressive disorder. METHOD: We tested nine symptom dimensions derived from a previously published factor analysis of depression rating scales as predictors of outcome in 811 adults with moderate to severe depression treated with flexibly dosed escitalopram or nortriptyline in Genome-based Therapeutic Drugs for Depression (GENDEP). The effects of symptom dimensions were tested in mixed-effect regression models that controlled for overall initial depression severity, age, sex and recruitment centre. Significant results were tested for replicability in 3637 adult out-patients with non-psychotic major depression treated with citalopram in level I of Sequenced Treatment Alternatives to Relieve Depression (STAR*D). RESULTS: The interest-activity symptom dimension (reflecting low interest, reduced activity, indecisiveness and lack of enjoyment) at baseline strongly predicted poor treatment outcome in GENDEP, irrespective of overall depression severity, antidepressant type and outcome measure used. The prediction of poor treatment outcome by the interest-activity dimension was robustly replicated in STAR*D, independent of a comprehensive list of baseline covariates. CONCLUSIONS: Loss of interest, diminished activity and inability to make decisions predict poor outcome of antidepressant treatment even after adjustment for overall depression severity and other clinical covariates. The prominence of such symptoms may require additional treatment strategies and should be accounted for in future investigations of antidepressant response.
Authors: Gerthe Veen; Irene M van Vliet; Roel H DeRijk; Erik J Giltay; Johannes van Pelt; Frans G Zitman Journal: Psychiatry Res Date: 2011-01-30 Impact factor: 3.222
Authors: Klaas J Wardenaar; Sophie A Vreeburg; Tineke van Veen; Erik J Giltay; Gerthe Veen; Brenda W J H Penninx; Frans G Zitman Journal: Biol Psychiatry Date: 2010-10-27 Impact factor: 13.382
Authors: Greg J Siegle; Stuart R Steinhauer; Edward S Friedman; Wesley S Thompson; Michael E Thase Journal: Biol Psychiatry Date: 2011-04-15 Impact factor: 13.382
Authors: Rudolf Uher; Ole Mors; Marcella Rietschel; Aleksandra Rajewska-Rager; Ana Petrovic; Astrid Zobel; Neven Henigsberg; Julien Mendlewicz; Katherine J Aitchison; Anne Farmer; Peter McGuffin Journal: J Clin Psychiatry Date: 2011-11 Impact factor: 4.384
Authors: Rudolf Uher; Mojca Zvezdana Dernovsek; Ole Mors; Joanna Hauser; Daniel Souery; Astrid Zobel; Wolfgang Maier; Neven Henigsberg; Petra Kalember; Marcella Rietschel; Anna Placentino; Julien Mendlewicz; Katherine J Aitchison; Peter McGuffin; Anne Farmer Journal: J Affect Disord Date: 2011-03-15 Impact factor: 4.839
Authors: R Uher; B Muthén; D Souery; O Mors; J Jaracz; A Placentino; A Petrovic; A Zobel; N Henigsberg; M Rietschel; K J Aitchison; A Farmer; P McGuffin Journal: Psychol Med Date: 2009-10-29 Impact factor: 7.723
Authors: Jonathan W Stewart; Patrick J McGrath; Maurizio Fava; Stephen R Wisniewski; Sidney Zisook; Ian Cook; Andrew A Nierenberg; Madhukar H Trivedi; G K Balasubramani; Diane Warden; Ira Lesser; A John Rush Journal: Int J Neuropsychopharmacol Date: 2009-04-03 Impact factor: 5.176
Authors: Joanna E Szczepanik; Maura L Furey; Allison C Nugent; Ioline D Henter; Carlos A Zarate; Carl W Lejuez Journal: Behav Res Ther Date: 2017-08-03
Authors: Chen X Chen; Susan Ofner; Giorgos Bakoyannis; Kristine L Kwekkeboom; Janet S Carpenter Journal: West J Nurs Res Date: 2017-09-15 Impact factor: 1.967
Authors: Ariela J E Kaiser; Carter J Funkhouser; Vijay A Mittal; Sebastian Walther; Stewart A Shankman Journal: Psychiatry Res Date: 2020-07-20 Impact factor: 3.222
Authors: Mario Maj; Dan J Stein; Gordon Parker; Mark Zimmerman; Giovanni A Fava; Marc De Hert; Koen Demyttenaere; Roger S McIntyre; Thomas Widiger; Hans-Ulrich Wittchen Journal: World Psychiatry Date: 2020-10 Impact factor: 49.548